Latest stories on CHRS
Coherus Oncology (CHRS) Reports Promising Phase 1b Trial Results in Esophageal Cancer
GuruFocus64 · neutralproduct/pr
Coherus Oncology announces clinical data from TREGCHECK development program
The Fly58 · neutralproduct/pr
Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development
StockTitan64 · neutralproduct/pr
Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development
Business Insider74 · bullishproduct/pr
Coherus to Participate in Upcoming Investor Conferences
Business Insider52 · neutralproduct/pr
Coherus to Participate in Upcoming Investor Conferences
GlobeNewswire52 · neutralproduct/pr
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
GlobeNewswire50 · neutralgeneral
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
Business Insider50 · neutralearnings
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
Business Insider53 · neutralproduct/pr
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
GlobeNewswire53 · neutralproduct/pr
Coherus Oncology Shares Down on Plans to Sell Biosimilar Assets
MarketWatch28 · bearishgeneral
Coherus Oncology retains Oppenheimer to market legacy biosimilar assets
The Fly55 · neutralgeneral
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
Business Insider55 · neutralgeneral
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
GlobeNewswire56 · neutralgeneral
Coherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
Baker Hughes Boosts Outlook on Chart Industries Acquisition
MarketWatch67 · bullishm&a
Coherus to Participate in Upcoming Investor Conferences
GlobeNewswire55 · neutralgeneral
Coherus Biosciences Launches $50 Million ATM Equity Program
TipRanks28 · bearishgeneral
Coherus Oncology, Inc. (CHRS) files 8-K
SEC 8-K50 · neutralgeneral
Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development
Seeking Alpha46 · neutralgeneral
Coherus Announces Special Dividend of Contingent Value Rights: Sharpened Focus on Oncology, Shareholder Value in Spotlight
MarketChameleon56 · neutralgeneral
Coherus Oncology issuing special dividend of biosimilar contingent value rights
The Fly50 · neutralgeneral
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
GlobeNewswire50 · neutralgeneral
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
StockTitan50 · neutralgeneral